Actelion Ltd., a leading biopharmaceutical company headquartered in Switzerland (CH), has established itself as a pioneer in the treatment of pulmonary arterial hypertension (PAH) and other rare diseases. Founded in 1997, Actelion has achieved significant milestones, including its acquisition by Johnson & Johnson in 2017, which further solidified its market position. The company focuses on innovative therapies, with core products such as Tracleer, Opsumit, and Uptravi, each designed to improve the quality of life for patients suffering from PAH. Actelion's commitment to research and development sets it apart, as it continually seeks to address unmet medical needs in the industry. With a strong presence in Europe, North America, and Asia, Actelion Ltd. remains a key player in the biopharmaceutical landscape, recognised for its contributions to advancing healthcare solutions.
We don't have data for Actelion Ltd, but we can show you information about their parent organization instead.
View parent company